Safety and Efficacy Study of the Xoft® Axxent® eBx® IORT System®

NAActive, not recruitingINTERVENTIONAL
Enrollment

1,200

Participants

Timeline

Start Date

May 8, 2012

Primary Completion Date

July 12, 2023

Study Completion Date

December 31, 2029

Conditions
Invasive Ductal CarcinomaDuctal Carcinoma in Situ
Interventions
RADIATION

Intra-operative Radiation Therapy - IORT

Single dose of 20 Gy

Trial Locations (24)

3165

Monash Health / Peter MacCallum Cancer Centre, Clayton

10305

Staten Island University Hospital, Staten Island

21204

Greater Baltimore Medical Center, Baltimore

21218

MedStar Oncology Network - Good Samaritan Hospital, Baltimore

21237

MedStar Oncology Network - Franklin Square, Baltimore

22191

Sentara Northern Virginia Medical Center, Woodbridge

33146

Doctors Hospital, Coral Gables

34747

Florida Hospital Celebration Health, Celebration

34994

Martin Health System Center for Clinical Research, Stuart

37212

Vanderbilt-Ingram Cancer Center, Nashville

37404

Parkridge Medical Center, Chattanooga

46804

Lutheran Hospital of Indiana, Fort Wayne

60612

Rush University, Chicago

73104

University of Oklahoma, Oklahoma City

80113

Swedish Medical Center, Englewood

80220

Western Surgical Care, PC, Denver

85704

University of Arizona, Tucson

90095

UCLA, Los Angeles

90806

Long Beach Memorial Medical Center, Long Beach

91010

City of Hope, Duarte

92056

Tri-City Medical Center, Oceanside

94523

Diablo Valley Oncology Hematology Medical Group, Pleasant Hill

03833

Exeter Hospital, Exeter

Unknown

Hospital CUF Porto, Porto

All Listed Sponsors
collaborator

Icad, Inc.

INDUSTRY

lead

Xoft, Inc.

INDUSTRY

NCT01644669 - Safety and Efficacy Study of the Xoft® Axxent® eBx® IORT System® | Biotech Hunter | Biotech Hunter